(29 June 2020) Remdesivir- (50.4% vs. 45.29%) significantly increased the discharge rate of patients with COVID-19

Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of
Randomized, Double-Blind, Placebo-Controlled Trials

https://doi.org/10.1101/2020.06.22.20136531

This study is registered at INPLASY (INPLASY202060046). PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for randomized controlled trials on the clinical
efficacy of remdesivir were searched. The main outcomes were discharge rate, mortality, and adverse events. Data of 1075 subjects showed that remdesivir significantly increased the discharge rate of patients with COVID-19 compared with the placebo (50.4% vs. 45.29%; relative risk [RR] 1.19 [95% confidence interval [CI], 1.05–1.34], I2 = 0.0%, P = 0.754). It also significantly decreased mortality (8.18% vs. 12.70%; RR 0.64 [95% CI, 0.44–0.92], I2 = 45.7%, P = 0.175) compared to the placebo. Data of 1296 subjects showed that remdesivir significantly decreased the occurrence of serious adverse events (RR 0.77 [95% CI, 0.63–0.94], I2 = 0.0%, P = 0.716). Remdesivir is reported to be efficacious and safe for the treatment of COVID-19.